These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17212760)

  • 41. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance.
    Bakke H; Lie K; Haugen IL; Korsvold GE; Høiby EA; Naess LM; Holst J; Aaberge IS; Oftung F; Haneberg B
    Infect Immun; 2001 Aug; 69(8):5010-5. PubMed ID: 11447180
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification.
    Zhang L; Wen Z; Lin J; Xu H; Herbert P; Wang XM; Mehl JT; Ahl PL; Dieter L; Russell R; Kosinski MJ; Przysiecki CT
    Vaccine; 2016 Jul; 34(35):4250-4256. PubMed ID: 27269057
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human T-cell responses after vaccination with the Norwegian group B meningococcal outer membrane vesicle vaccine.
    Naess LM; Oftung F; Aase A; Wetzler LM; Sandin R; Michaelsen TE
    Infect Immun; 1998 Mar; 66(3):959-65. PubMed ID: 9488382
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.
    Moe GR; Zuno-Mitchell P; Hammond SN; Granoff DM
    Infect Immun; 2002 Nov; 70(11):6021-31. PubMed ID: 12379678
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Porin A-specific antibody avidity in patients who are convalescing from meningococcal B disease.
    Vermont CL; van Dijken HH; de Groot R; van den Dobbelsteen GP
    Pediatr Res; 2005 Jul; 58(1):149-52. PubMed ID: 15774845
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neisseria meningitidis B vaccines: recent advances and possible immunization policies.
    Gasparini R; Amicizia D; Domnich A; Lai PL; Panatto D
    Expert Rev Vaccines; 2014 Mar; 13(3):345-64. PubMed ID: 24476428
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups.
    Pinto VB; Moran EE; Cruz F; Wang XM; Fridman A; Zollinger WD; Przysiecki CT; Burden R
    Vaccine; 2011 Oct; 29(44):7752-8. PubMed ID: 21827811
    [TBL] [Abstract][Full Text] [Related]  

  • 48. IgG antibody levels to meningococcal porins in patient sera: comparison of immunoblotting and ELISA measurements.
    Wedege E; Bolstad K; Wetzler LM; Guttormsen H
    J Immunol Methods; 2000 Oct; 244(1-2):9-15. PubMed ID: 11033014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.
    Gorringe AR; Taylor S; Brookes C; Matheson M; Finney M; Kerr M; Hudson M; Findlow J; Borrow R; Andrews N; Kafatos G; Evans CM; Read RC
    Clin Vaccine Immunol; 2009 Aug; 16(8):1113-20. PubMed ID: 19553555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlers.
    Jackson C; Lennon D; Wong S; Yan J; Stewart J; Reid S; Oster P; Ypma E; Martin D
    Arch Dis Child; 2011 Aug; 96(8):744-51. PubMed ID: 21596727
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles.
    Zariri A; van Dijken H; Hamstra HJ; van der Flier M; Vidarsson G; van Putten JP; Boog CJ; van den Dobbelsteen G; van der Ley P
    Vaccine; 2013 Nov; 31(47):5585-93. PubMed ID: 23933369
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.
    Zhu D; Zhang Y; Barniak V; Bernfield L; Howell A; Zlotnick G
    Infect Immun; 2005 Oct; 73(10):6838-45. PubMed ID: 16177362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Avidity of serogroup A meningococcal IgG antibodies after immunization with different doses of a tetravalent A/C/Y/W135 polysaccharide vaccine.
    Bårnes GK; Naess LM; Rosenqvist E; Guerin PJ; Caugant DA;
    Scand J Immunol; 2011 Jul; 74(1):87-94. PubMed ID: 21332570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae.
    Leduc I; Connolly KL; Begum A; Underwood K; Darnell S; Shafer WM; Balthazar JT; Macintyre AN; Sempowski GD; Duncan JA; Little MB; Rahman N; Garges EC; Jerse AE
    PLoS Pathog; 2020 Dec; 16(12):e1008602. PubMed ID: 33290434
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of phenotypically indistinguishable but geographically distinct Neisseria meningitidis Group B isolates in a serum bactericidal antibody assay.
    Findlow J; Holland A; Andrews N; Weynants V; Sotolongo F; Balmer P; Poolman J; Borrow R
    Clin Vaccine Immunol; 2007 Nov; 14(11):1451-7. PubMed ID: 17881507
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine.
    Zollinger WD; Donets MA; Schmiel DH; Pinto VB; Labrie JE; Moran EE; Brandt BL; Ionin B; Marques R; Wu M; Chen P; Stoddard MB; Keiser PB
    Vaccine; 2010 Jul; 28(31):5057-67. PubMed ID: 20653107
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB.
    Martin DR; Ruijne N; McCallum L; O'Hallahan J; Oster P
    Clin Vaccine Immunol; 2006 Apr; 13(4):486-91. PubMed ID: 16603616
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children.
    Findlow J; Lowe A; Deane S; Balmer P; van den Dobbelsteen G; Dawson M; Andrews N; Borrow R
    Vaccine; 2005 Apr; 23(20):2623-7. PubMed ID: 15780445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine.
    Naess LM; Aarvak T; Aase A; Oftung F; Høiby EA; Sandin R; Michaelsen TE
    Vaccine; 1999 Feb; 17(7-8):754-64. PubMed ID: 10067680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement of surface protein antigens, PorA and PorB, in Bexsero vaccine using quantitative mass spectrometry.
    Whiting G; Vipond C; Facchetti A; Chan H; Wheeler JX
    Vaccine; 2020 Feb; 38(6):1431-1435. PubMed ID: 31839469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.